Valeant Pharmaceuticals has decided to restructure its operations into three...

Valeant Pharmaceuticals has decided to restructure its operations into three segments. Bausch & Lomb and most of the group's international operations will belong to the durable growth segment, which will represent about half of Valeant's total turnover. The group is also considering the disposal of some core and non-core activities ...

To continue reading this article register now.

Already an Eyewear Intelligence subscriber? Sign in here.

barrier_image_OIC

Become a member today for full access from just €6,70 a week!

Buying a membership today will give you:

  • Unlimited access to ewintelligence.com - all insight and analysis available online
  • Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
  • Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
  • Case studies and best practices on business challenges
  • Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
  • Access to over 11,500 articles and analyses in the archive
  • Personal library to save articles and track your key content
  • Powerful search and intuitive navigation

Or sign-up for a trial month for just 9,90€. To continue reading this article register now.